Lipella Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 7
- Market Cap
- $3.7M
- Website
- http://www.lipella.com
Evaluating LP-10 in Subjects With OLP
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Lipella Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06233591
- Locations
- 🇺🇸
UCSF School of Dentistry, San Francisco, California, United States
🇺🇸Center for Dermatology, Fremont, California, United States
🇺🇸Miami Cancer Institue at Baptist Health, Inc, Miami, Florida, United States
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Lipella Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03129126
- Locations
- 🇺🇸
Michigan Institute of Urology, Troy, Michigan, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Premier Medical Group, Poughkeepsie, New York, United States
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Lipella Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT01393223
- Locations
- 🇺🇸
William Beaumont Hospitals, Royal Oak, Michigan, United States
© Copyright 2024. All Rights Reserved by MedPath